Targeted Therapies in Advanced and Metastatic Urothelial Carcinoma.

Katims, Andrew B; Reisz, Peter A; Nogueira, Lucas; Truong, Hong; Lenis, Andrew T; Pietzak, Eugene J; Kim, Kwanghee; Coleman, Jonathan A

Katims, Andrew B; Reisz, Peter A; Nogueira, Lucas; Truong, Hong; Lenis, Andrew T; Pietzak, Eugene J; Kim, Kwanghee; Coleman, Jonathan A.

Afiliação

Katims AB; Urology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
Reisz PA; Urology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
Nogueira L; Urology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
Truong H; Urology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
Lenis AT; Urology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
Pietzak EJ; Urology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
Kim K; Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.
Coleman JA; Urology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA.

Cancers (Basel) ; 14(21)2022 Nov 04.

Article em En | MEDLINE | ID: mdl-36358849

Palavras-chave

antibody-drug conjugates; antineoplastic therapy; immunotherapy; metastatic urothelial carcinoma; molecular targeted therapy; monoclonal antibodies; next-generation sequencing; tumor biomarkers

Texto completo

Adicionar na Minha BVS

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Bases de dados: MEDLINE Idioma: En Revista: Cancers (Basel) Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Estados Unidos